Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands
Authors' conclusion
Based on these analyses, the 50% tapering approach saved the highest cost per QALY lost.
Study context
- Population
- Dutch patients with rheumatoid arthritis (RA) on biological disease-modifying antirheumatoid drugs (bDMARDs) (simulated cohort)
- Comparison
- bDMARD tapering strategies vs continuation
- Outcome
- ICER (cost per QALY lost) of each tapering strategy vs continuation, societal perspective
- Follow-up
- 30 years
Methodological detailsMarkov model, societal perspective, life-time horizon of 30 years, 3-monthly transitions between DAS28-defined health states, deterministic and probabilistic sensitivity analyses, multiple scenario analyses
- Markov model
- Societal perspective
- Life-time horizon of 30 years
- 3-monthly transitions between DAS28-defined health states
- Deterministic and probabilistic sensitivity analyses
- Multiple scenario analyses
Main finding
As reported in the abstract
ICER vs continuation
| Outcome | Tapering | De-escalation | Discontinuation |
|---|---|---|---|
| ICER vs continuation · 30 years | 115 157 €/QALY lost | 74 226 €/QALY lost | 67 137 €/QALY lost |
| Probability cost-effective (WTA €50 000/QALY lost) | 76.1% | 64.3% | 60.1% |
- Probability of a loss in quality of life
- 72.8%
Original publication
Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Ann Rheum Dis. Published 9 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →